Frenova Renal Research, the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research, announced today that its F1RST Up™ alliance of clinical research sites focusing on kidney disease has expanded to include 55 physician-investigators representing 23 sites.
Kurt Mussina, general manager of Frenova, “The success of F1RST Up is clear evidence of the value the alliance provides to our sponsor clients, our alliance partners and to other contract research organizations (CROs) we collaborate with.” He went on to say, “F1RST Up accelerates study startup by taking a no-nonsense approach to driving low-value administrative and contracting burdens out of the startup process. This provides our partners and customers with a better startup experience, equating to much better value.”
The F1RST Up alliance membership includes nephrology practices caring for large numbers of chronic kidney disease (CKD) patients, including end-stage renal disease (ESRD) patients. F1RST Up investigators are highly experienced clinical researchers in renal disease and its adjacencies, including vascular access and care, cardio-renal conditions, rare diseases, infectious diseases and transplant. The alliance leverages Frenova’s access to proprietary clinical research assets to inform protocol design and to carry out highly targeted and efficient patient recruitment efforts.
On the formation of this alliance: “We formed this alliance with the leading physician-investigators from across Frenova’s network of 260 clinical research sites,” said Christina Kahn, Frenova’s F1RST Up alliance lead. “This is important because it means F1RST Up offers sponsors access to a uniquely concentrated source of both high-quality renal research sites and a substantial number of patients.”